Table 1.
Baseline characteristics of incl uded studies
| Study | Phase | Sample size | Age Median (Range) |
dMMR | pMMR | PD-L1 (+) | PD-L1 (-) | Regimen | |
|---|---|---|---|---|---|---|---|---|---|
| Arms | N | ||||||||
|
MITO END-3 (2023) [25] |
2 | Study | 63 | 66(61–72) | 26 | 35 | 23 | 39 | Avelumab plus carboplatin and paclitaxel |
| Control | 62 | 65(56–70) | 31 | 29 | 24 | 35 | Carboplatin and paclitaxel | ||
| DUO-E (2023) [21] | 3 | Study | 477 | 64(22–84) | 46 | 192 | 170 | 61 | Durvalumab plus carboplatin and paclitaxel |
| Control | 238 | 64(31–85) | 49 | 192 | 163 | 75 | Carboplatin and paclitaxel | ||
| NRG GY018 (2025) [23] | 3 | Study | 404 | 67.2 (39.0–82.0)a | 110 | 294 | 294 | 102 | Pembrolizumab plus carboplatin and paclitaxel |
| 66.2 (31–94.0)b | |||||||||
| Control | 406 | 66.0 (37.0–86.0)a | 112 | 294 | 302 | 97 | Carboplatin and paclitaxel | ||
| 66.1 (29.0–91.0)b | |||||||||
| AtTEnd (2024) [24] | 3 | Study | 360 | 67 (61–73) | 81 | 269 | 86 | 247 | Atezolizumab plus carboplatin and paclitaxel |
| Control | 189 | 65 (60–73) | 44 | 140 | 44 | 129 | Carboplatin and paclitaxel | ||
|
RUBY (2023) [22] |
3 | Study | 245 | 64(41–81) | 53 | 192 | NR | NR | Dostarlimab plus carboplatin and paclitaxel |
| Control | 249 | 65(28–85) | 65 | 184 | NR | NR | Carboplatin and paclitaxel | ||
PD-L1 programmed cell death ligand 1, dMMR deficient mismatch repair, pMMR proficient mismatch repair, RCT randomized controlled trial, NR not reported
a dMMR subgroup; b pMMR subgroup